孕激素与选择性孕激素受体调节剂作用于子宫肌瘤的两种不同机制的功能性证据
实验室研究比较醋酸乌利司他治疗2个月、未治疗子宫肌瘤及健康子宫肌层组织的转录特征,发现孕激素通过TGF-β/SMAD3通路促进肌瘤增殖与细胞外基质重塑,而醋酸乌利司他抑制这些过程,核与膜孕激素受体均参与肌瘤病理生物学。
要点
- 孕激素激活TGF-β和SMAD3信号通路,促进子宫肌瘤增殖、生长及细胞外基质重塑。
- 醋酸乌利司他对上述过程具有抑制作用。
- 核孕激素受体与膜孕激素受体在子宫肌瘤病理生物学中发挥不同作用。
核心结论
- 核孕激素受体与膜孕激素受体均与子宫肌瘤治疗相关,尤其在与选择性孕激素受体调节剂联合时。
- 作者认为,选择性孕激素受体调节剂联合或不联合直接及间接靶向细胞外基质(通过特定的TGF-β和SMAD3信号通路)的新型治疗策略,可能成为子宫肌瘤的治疗选择。
研究设计与样本
- 实验室研究,标本来自波兰比亚韦斯托克医科大学生殖与妇科内分泌学系及生物样本库。
- 研究对象为诊断为不孕相关子宫肌瘤的育龄期女性,接受子宫肌瘤剔除术,术前接受选择性孕激素受体调节剂醋酸乌利司他治疗或未接受任何药物预处理。
- 醋酸乌利司他组每日5 mg/d治疗2个月(n=100),未治疗子宫肌瘤组(n=150),健康子宫肌层对照组织(n=100)。
- 手术切除后立即采集组织样本进行转录分析和评估。
主要发现
- 孕激素激活转化生长因子-β(TGF-β)和SMAD3信号通路,并通过上调SMAD3、TGF-β受体1型和2型、Ras homolog A、血管内皮生长因子,或增加纤维化相关基因I型胶原α-1链和前胶原I型α-1链的生成,促进子宫肌瘤的增殖、生长和细胞外基质重塑。
- 醋酸乌利司他对上述过程具有抑制作用。
- 核孕激素受体与膜孕激素受体在子宫肌瘤病理生物学中发挥不同作用。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the specific mechanisms through which progesterone and selective progesterone receptor modulators impact the growth, synthesis, and accumulation of the extracellular matrix in uterine leiomyomas. DESIGN: Laboratory study. SETTING: Academic Research Institutions. PATIENTS (S): This study involved reproductive-age women diagnosed with infertility associated uterine leiomyomas who underwent myomectomy either after selective progesterone receptor modulator ulipristal acetate (UA) treatment or without any pharmacological pretreatment. Control samples included healthy myometrium tissue (n = 100). Specimens were obtained from the Department of Reproduction and Gynecological Endocrinology and Biobank, Medical University of Bialystok, Poland. INTERVENTIONS: Daily (5 mg/d) UA treated for 2 months (n = 100) and untreated (n = 150) patients with uterine leiomyomas or normal healthy myometrium (n = 100) tissue samples immediately after surgery were collected for transcriptional analysis and assessments. MAIN OUTCOME MEASURES: Progesterone-induced activation of the signaling pathways related to uterine leiomyomas extracellular matrix synthesis, deposition, and growth, as well as the expression profile of progesterone receptors in uterine leiomyomas, were assessed. RESULTS: The results indicated that progesterone activated the transforming growth factor-β and SMAD3 signaling pathways and promoted proliferation, growth, and extracellular matrix remodeling in uterine leiomyomas by up-regulating SMAD3, transforming growth factor-β (TGF-β) receptor type 1 and II, Ras homolog A, vascular endothelial growth factor, or increasing the fibrosis-related gene collagen, type I, ɑ-1, and procollagen, type I, ɑ-1 production. In contrast, UA had inhibitory effects on these processes. The study also showed that both nuclear and membrane progesterone receptors play distinct roles in uterine leiomyoma pathobiology. CONCLUSIONS: We showed that both nuclear and membrane progesterone receptors were relevant in the treatment of uterine leiomyomas, especially when combined with selective progesterone receptor modulators. Novel therapeutic approaches combining selective progesterone receptor modulators with or without direct and indirect extracellular matrix targeting through selected specifically TGF-β and SMAD3 (SMAD3, TGF-β receptor types 1 and II, Ras homolog A, vascular endothelial growth factor, collagen, type I, ɑ-1) signaling pathways could therefore be a treatment option for uterine leiomyomas.
引用
- Milewska G, Ponikwicka-Tyszko D, Bernaczyk P, et al. Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas. Fertil Steril. 2024. PMID: 38431184. doi:10.1016/j.fertnstert.2024.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。